Previous studies have reported that patients with a higher PD-L1 expression level have a better immunotherapy response, especially with PD-1/PD-L1 blockade, and PD-L1 expression was considered as a predictive biomarker of immunotherapy in diverse cancers [12, 28–33]. The gene discussed is PDCD1; the disease is cancer.